Dr. Reddy’s to delay semaglutide supplies due to quality isssue, shares hit
Dr. Reddy’s Laboratories has delayed commercial supplies of its semaglutide drug due to quality issues with the active pharmaceutical ingredient. The company's shares fell over 5% following the announcement, though it maintains that patient safety remains unaffected.
Why it matters
The delay impacts the availability of affordable generic versions of high-demand metabolic drugs, highlighting the complexities of pharmaceutical supply chain quality control.
Dr. Reddy’s Laboratories has decided to delay commercial supplies of semaglutide due to an issue associated with the active pharmaceutical ingredient (API) used in the drug, an announcement on Thursday (July 9, 2026) that saw the generic drugmaker’s shares plunge.
The article provides a balanced report on corporate news, including the company's official statement and market reaction.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in